Advertisement

PentaVision

Retinal Physician

Article | 2026 ASRS Meeting

A First Look at Phase 2 ArMaDa Data

Arshad M. Khanani, MD, FASRS, discusses phase 2 findings for OCU410, an investigational gene therapy for geographic atrophy. A phase 3 program is expected to begin later this year.

By: Arshad M. Khanani, MD, MA, FASRS
Retinal Physician July 19, 2026

Clinical Report: A First Look at Phase 2 ArMaDa Data

Overview

The phase 2 ArMaDa study evaluated OCU410, a gene therapy for geographic atrophy (GA), showing a 34% reduction in GA growth with the medium dose compared to control. No serious safety concerns were reported.

Background

Geographic atrophy (GA) is an advanced form of non-neovascular age-related macular degeneration (AMD) that leads to vision loss. Current treatment options are limited, making the development of new therapies critical. OCU410 represents a novel approach using gene therapy to modulate inflammatory processes associated with GA.

Data Highlights

ParameterMedium DoseControl
GA Growth Reduction34%Baseline
Patients per Cohort1717

Key Findings

  • OCU410 is a one-time gene therapy designed for GA treatment.
  • The phase 2 study included two dose cohorts: medium-dose (1x10¹⁰ vg/eye) and high-dose (3×10¹⁰ vg/eye).
  • A 34% reduction in GA growth was observed in the medium-dose group compared to control.
  • OCU410 was well tolerated with no cases of retinal vasculitis or endophthalmitis reported.
  • A phase 3 program for OCU410 is expected to begin later this year.

Clinical Implications

The findings suggest that OCU410 may provide a new treatment option for patients with geographic atrophy. The favorable safety profile is particularly relevant for clinicians considering new therapies for GA.

Conclusion

OCU410 is a novel gene therapy for geographic atrophy, with a reported 34% reduction in GA growth in the medium-dose group compared to control.

Related Resources & Content

  1. Ocugen, Inc., Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration, 2026
  2. Retinal Physician, Ocugen Reports Preliminary Data, 2024
  3. The Ophthalmologist, Ocugen GA Trial Advances Toward Phase 3, 2026
  4. Retinal Physician — Video: Can Vonaprument Slow Vision Loss in GA?
  5. Retinal Physician — Annexon Completes ARCHER Enrollment
  6. Age-Related Macular Degeneration Preferred Practice Pattern® - Ophthalmology
  7. Comprehensive Adult Medical Eye Evaluation Preferred Practice Pattern® - Ophthalmology
  8. Committed to improving
  9. SYFOVRE (pegcetacoplan injection) Prescribing Information
  10. Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial - ScienceDirect
  11. Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE - PubMed
  12. New ReST Committee Report Published in JVRD Summarizes Analysis of Reported Cases of Retinal Vasculitis Following Syfovre Injection - The American Society of Retina Specialists
  13. GT005 (PPY988): Development Program in Geographic Atrophy | Novartis
  14. Ocular biomarker profiling after complement factor I gene therapy in geographic atrophy secondary to age-related macular degeneration | medRxiv
  15. Study Details | NCT05811351 | A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | ClinicalTrials.gov
  16. Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Ocugen, Inc.
  17. Ocugen Provides Business Update with First Quarter 2026 Financial Results | Ocugen, Inc.